Industry news

Google made investment in new antibiotics startup

GMP News

GV, the venture capital arm of Google, led an estimated $51 million investment round in Spero Therapeutics, a Cambridge, Massachusetts-based biotech developing a new class of antibiotic treatments targeting some of the toughest drug-resistant bacterial infections.

Big Data: Is It Crunch Time for Pharma?

Julian Upton / Pharmaceutical Executive

With big data and advanced analytics progressing from fad to frontier status, Pharm Exec examines the readiness of the biopharma industry to take advantage of this promise. Can new digital health tools be harnessed to help advance new treatment approaches and aid decision-making? 

20 March 2017

Neothetics Announces Last Subject Enrolled in Phase 2 Proof of Concept Trial for LIPO-202 for the Reduction of Submental Subcutaneous Fat

Neothetics, Inc. (NASDAQ:NEOT), a clinical-stage specialty pharmaceutical company developing therapeutics for the aesthetic market today announced completion of subject enrollment for its Phase 2 proof of concept trial, LIPO-202-CL-31, for the reduction of submental subcutaneous fat.  

The UK's Catapult to Drug Discovery Collaboration

Julian Upton / Pharmaceutical Executive

Pharm Exec speaks to Chris Molloy, CEO of the Medicines Discovery Catapult, about how the organization aims to establish new approaches that draw on the combined strengths of the UK’s private, public and not-for-profit sectors to grow and sustain the country’s reputation for innovative, fast-to-patient drug discovery.

20 March 2017

2017 NVCA Yearbook Highlights Busy Year for Venture Industry and NVCA

National Venture Capital Association

The National Venture Capital Association (NVCA) today released the 20th edition of the annual NVCA Yearbook, documenting trends and analysis of venture capital activity in the United States from the past year and capturing historical data and information about venture’s role in fueling entrepreneurship in America. The report shows that the number of life science deals as a share of overall venture deal count increased to 12.5% in 2016.

17 March 2017

Miramar Labs, Inc.® Reports Fourth Quarter and Full Year 2016 Financial Results

Miramar Labs, Inc., (OTCQB:MRLB), a global aesthetic company, announced today financial results for fourth quarter and full year ended December 31, 2016. 2016 revenue of $20.4 million, up 19% year-over-year. Strong sales in North America with year-over-year growth of 38%. Gross margin expands to 55% in 2016, up from 52% in the prior year.

Will Pharma Manufacturing Move Back to the US?

Jim Miller / BioPharm International

The bio/pharmaceutical industry is still buzzing about President Trump’s meeting with pharmaceutical executives on Jan. 31, 2017 (1). While promising the industry lower taxes and less regulation, the President emphasized that those benefits will come only if the industry lowers drug prices and moves more manufacturing back to the United States.

Russian Ministry will establish new bio-targets for drug analogues developing

GMP News

The Ministry of Industry and Trade of Russia will make changes to the List of bio-targets for developing the analogs of innovative medicinal products that are similar and improved in terms of their pharmacotherapeutic effect.

UK life sciences sector productivity double national average

Steve Bremer / europien pharmaceutical review

The PwC report, commissioned by the Association of the British Pharmaceutical Industry (ABPI) and supported by the Association of the British Healthcare Industry (ABHI), the BioIndustry Association (BIA), and the British In Vitro Diagnostics Association (BIVDA), shows that the average productivity of UK life sciences employees, expressed as gross value added (GVA), is £104,000, compared to the UK average of £49,000.

Top 15 pharma companies by 2016 revenue

Eric Palmer / Fierce Pharma

The biopharma industry is so dynamic and has had so many watershed moments for one reason or another that for someone to proclaim a new one is pretty pointless. Still, it does feel as if something's happening here. The building tensions over pricing, and a review of the top 15 companies by 2016 revenues, suggests the relentless march forward of drug prices and profits may have slowed.